Atea Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Atea Pharmaceuticals Inc cash flow-to-debt ratio. Atea Pharmaceuticals Inc (AVIR) has a Cash Flow-to-Debt Ratio of -1.32x as of June 2026, meaning its operating cash flow of $-37.08 Million could theoretically repay -1% of its total liabilities ($28.12 Million) in one year. Check Atea Pharmaceuticals Inc (AVIR) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Atea Pharmaceuticals Inc (2018–2025)
Cash flow-to-debt ratio of Atea Pharmaceuticals Inc from 2018 to 2025. Historical debt coverage capacity for Atea Pharmaceuticals Inc across 8 annual periods. Check cash flow reinvestment rate of Atea Pharmaceuticals Inc to assess the company's total reinvestment commitment from operating cash flow.
Atea Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2018–2025)
Atea Pharmaceuticals Inc cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Atea Pharmaceuticals Inc. For the full cash flow conversion analysis, see Atea Pharmaceuticals Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.32x | $-132.03 Million | $39.78 Million | ▲ +36.8% |
| 2024 | -5.25x | $-135.50 Million | $25.80 Million | ▼ -144.6% |
| 2023 | -2.15x | $-85.39 Million | $39.78 Million | ▲ +53.6% |
| 2022 | -4.63x | $-120.98 Million | $26.14 Million | ▼ -234.2% |
| 2021 | -1.39x | $-87.00 Million | $62.81 Million | ▼ -247.4% |
| 2020 | 0.94x | $296.73 Million | $315.83 Million | ▲ +625.3% |
| 2019 | -0.18x | $-12.81 Million | $71.64 Million | ▼ -60.6% |
| 2018 | -0.11x | $-7.91 Million | $71.02 Million | — |